| Literature DB >> 34335272 |
Baoyue Zhang1, Jun Zhao1, Zhe Wang1, Pengfei Guo1, Ailin Liu1, Guanhua Du1.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease that seriously threatens the health of the elderly. At present, no drugs have been proven to cure or delay the progression of the disease. Due to the multifactorial aetiology of this disease, the multi-target-directed ligand (MTDL) approach provides an innovative and promising idea in search for new drugs against AD. In order to find potential multi-target anti-AD drugs from traditional Chinese medicine (TCM) formulae, a compound database derived from anti-AD Chinese herbal formulae was constructed and predicted by the anti-AD multi-target drug prediction platform established in our laboratory. By analyzing the results of virtual screening, 226 chemical constituents with 3 or more potential AD-related targets were collected, from which 16 compounds that were predicted to combat AD through various mechanisms were chosen for biological validation. Several cell models were established to validate the anti-AD effects of these compounds, including KCl, Aβ, okadaic acid (OA), SNP and H2O2 induced SH-SY5Y cell model and LPS induced BV2 microglia model. The experimental results showed that 12 compounds including Nonivamide, Bavachromene and 3,4-Dimethoxycinnamic acid could protect model cells from AD-related damages and showed potential anti-AD activity. Furthermore, the potential targets of Nonivamide were investigated by molecular docking study and analysis with CDOCKER revealed the possible binding mode of Nonivamide with its predicted targets. In summary, 12 potential multi-target anti-AD compounds have been found from anti-AD TCM formulae by comprehensive application of computational prediction, molecular docking method and biological validation, which laid a theoretical and experimental foundation for in-depth study, also providing important information and new research ideas for the discovery of anti-AD compounds from traditional Chinese medicine.Entities:
Keywords: Alzheimer’s disease; molecular docking; multi-target; traditional Chinese medicine; virtual screening
Year: 2021 PMID: 34335272 PMCID: PMC8322649 DOI: 10.3389/fphar.2021.709607
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1The analysis of protein-protein interaction network of AD-related targets by STRING.
Basic information of AD-related targets.
| Target symbol | Target name | Classification of targets |
|---|---|---|
| ACHE | Acetylcholinesterase | cholinergic system dysfunction |
| BCHE | Butyrylcholinesterase | cholinergic system dysfunction |
| CHRM1 | muscarnic m1 receptor | cholinergic system dysfunction |
| CHRM2 | muscarnic m2 receptor | cholinergic system dysfunction |
| CHRNA4 | nicotinic acetylcholine receptor α4 | cholinergic system dysfunction |
| CHRNA7 | nicotinic acetylcholine receptor α7 | cholinergic system dysfunction |
| GRIA1 | α-amino-3-hydroxy-5-methyl-4-isoxa-zolep-propionate 1 receptor | glutamate/GABA system dysfunction |
| GRIA2 | α-amino-3-hydroxy-5-methyl-4-isoxa-zolep-propionate 2 receptor | glutamate/GABA system dysfunction |
| GABRG1 | gamma-aminobutyric acid A receptor | glutamate/GABA system dysfunction |
| GABBR1 | gamma-aminobutyric acid B receptor | glutamate/GABA system dysfunction |
| GRM2 | metabotropic glutamate receptor 2 | glutamate/GABA system dysfunction |
| GRM3 | metabotropic glutamate receptor 3 | glutamate/GABA system dysfunction |
| GRIN1 | N-methyl-D-aspartate receptor | glutamate/GABA system dysfunction |
| APP | beta-amyloid precursor protein | aggregates of amyloid-β peptide |
| BACE1 | β-secreatase | aggregates of amyloid-β peptide |
| PSEN1 | gamma seretase | aggregates of amyloid-β peptide |
| HSP90AA1 | heat shock protein 90 | hyper-phosphorylated tau |
| CDK5 | cyclin-dependent kinase 5 | hyper-phosphorylated tau |
| GSK3B | glycogen synthase kinase 3 beta | hyper-phosphorylated tau |
| MAPT | microtubule-associated protein tau | hyper-phosphorylated tau |
| PIN1 | peptidyl prolyl cis/trans Isomerases | hyper-phosphorylated tau |
| HTR1A | 5 hydroxytryptamine 1A receptor | serotonergic system dysfunction |
| HTR2A | 5 hydroxytryptamine 2A receptor | serotonergic system dysfunction |
| HTR3A | 5 hydroxytryptamine 3A receptor | serotonergic system dysfunction |
| HTR4 | 5 hydroxytryptamine 2 receptor | serotonergic system dysfunction |
| HTR6 | 5 hydroxytryptamine 6 receptor | serotonergic system dysfunction |
| MAOB | Monoamine oxidase B | oxidative stress |
| MPO | Myeloperoxidae | oxidative stress |
| PDE4A | phosphodiesterase type 4A | oxidative stress |
| PDE4B | phosphodiesterase type 4B | oxidative stress |
| PDE9A | phosphodiesterase type 9A | oxidative stress |
| MAPK8 | c-Jun N-terminal kinase-1 | neuroinflammation |
| MAPK9 | c-Jun N-terminal kinase-2 | neuroinflammation |
| MAPK10 | c-Jun N-terminal kinase-3 | neuroinflammation |
| MAPKAPK3 | p38α mitogen-activated protein kinase | neuroinflammation |
| CHUK | nuclear factor kappa-B kinase alpha | neuroinflammation |
| IKBKB | nuclear factor kappa-B kinase beta | neuroinflammation |
| NOS2 | inducible nitric oxide synthase | neuroinflammation |
| PPARG | Peroxisome proliferator-activated receptor gamma | neuroinflammation |
| TNF | tumor necrosis factor alpha | neuroinflammation |
| ADORA2A | A2A adenosine receptor | neuroinflammation |
| ALOX12 | 12-lipoxygenase | neuroinflammation |
| PTGS2 | cyclooxygenase-2 | neuroinflammation |
| PPID | Cyclophilin D | mitochondrial dysfunction |
| PDHX | pyruvate dehydrogenase | mitochondrial dysfunction |
| ACAT1 | Cholesterol Acyltransferase | Other |
| COMT | catechol O-methyltransferase | Other |
| ESR1 | estrogen receptor α | Other |
| HRH3 | histamine H3 receptor | Other |
| HMGCS1 | 3-hydroxy-3-methyl glutaryl coenzyme A reductase | Other |
| IDE | insulin-degrading enzyme | Other |
| SIGMAR1 | sigma-1 receptor | Other |
FIGURE 2Examples of the top 15 good (A) and bad (B) fragments for ACHE inhibition as estimated by NB(ECFP_6) model. The Bayesian score (Score) is given for each fragment.
FIGURE 3ADMET properties diversity distribution of 226 chemical constituents. ADMET_AlogP98: lipid-water partition coefficient; ADMET_PSA_2D: polar molecular surface area; 2D plots of ADMET_PSA_2D and ADMET_AlogP98 show 2 series of ellipses representing the 95 and 99% confidence regions of the blood-brain barrier permeability (BBB) model, and the human intestinal absorption (HIA) model 95 and 99% CI.
FIGURE 4The number of potential active chemical constituents from different Chinese medicinal herbs.
FIGURE 5The number of potential active chemical constituents and the number of their predicted targets.
FIGURE 6Workflow of the integrated virtual screening and drug screening approaches for anti-AD multi-target compounds from TCM formulae.
FIGURE 7The compound-target network for potential anti-AD chemical constituents. The purple rectangle means chemical constituents, and the orange means predicted target.
The 16 typical examples of multi-target compounds.
| Compound name | Chemical structure | Predicted targets |
|---|---|---|
| L-Arctigenin |
| ALOX12, ACHE, PTGS2, ESR1, GABRG1, GSK3B, PDE4A, TNF |
| Dihydrocapsaicin |
| ALOX12, ACHE, PTGS2, ESR1 |
| Rhapontigenin |
| ALOX12, ACHE, APP, PTGS2, ESR1, GSK3B, NOS2, MAOB, MAPT, TNF |
| 6-Shogaol |
| ALOX12, ACHE, PTGS2, MAOB |
| 6-Gingerol |
| ALOX12, ACHE, PTGS2, TNF |
| 10-Gingerol |
| ALOX12, ACHE, PTGS2, TNF |
| Isorhapontigenin |
| ALOX12, ACHE, APP, PTGS2, ESR1, GSK3B, MAOB, MAPT, TNF |
| Nonivamide |
| ALOX12, ACHE, PTGS2, ESR1, MAOB |
| Flavokawain B |
| ALOX12, ACHE, APP, PTGS2, ESR1, GABRG1, GSK3B, NOS2, MAOB, MAPT, TNF |
| Demethoxycurcumin |
| ALOX12, ACHE, APP, PTGS2, GSK3B, MAOB, MAPT |
| Bisdemethoxycurcumin |
| ALOX12, ACHE, APP, PTGS2, GSK3B, MAOB |
| Carnosol |
| PTGS2, ESR1, TNF |
| Cardamonin |
| ALOX12, ACHE, APP, PTGS2, ESR1, GABRG1, GSK3B, NOS2, MAOB, MAPT, TNF |
| Matairesinol |
| ALOX12, ACHE, BACE1, PTGS2, ESR1, GABRG1, GSK3B, PDE4A, TNF |
| Bavachromene |
| ACHE, APP, PTGS2 |
| 3,4-Dimethoxycinnamic acid |
| ACHE, APP, PTGS2, GSK3B |
FIGURE 8Various compounds suppressed KCl-induced cytotoxicity in SH-SY5Y cells. Cells were pretreated with different concentrations of Nonivamide (A), Demethoxycurcumin (B), Matairesinol (C), Bavachromene (D), 3,4-Dimethoxycinnamic acid (E) or 0.1% DMSO for 2 h and then incubated with or without KCl (80 mM) for 24 h and the cell viability was detected by MTT assay. Results are shown as the mean ± SEM and represent three independent experiments. ###p < 0.001 compared with control group, *p < 0.05, **p < 0.01, ***p < 0.001 compared with KCl treated group.
FIGURE 9Various constituents suppressed Aβ-induced cytotoxicity in SH-SY5Y cells. Cells were pretreated with different concentrations of Nonivamide (A), 3,4-Dimethoxycinnamic acid (B) or 0.1% DMSO for 2 h and then incubated with or without Aβ1–42 (10 μM) for 24 h and the cell viability was detected by MTT assay. Results are shown as the mean ± SEM and represent three independent experiments. ###p < 0.001 compared with control group, ***p < 0.001 compared with Aβ treated group.
FIGURE 10Various constituents suppressed OA-induced cytotoxicity in SH-SY5Y cells. Cells were pre-treated with different concentrations of Flavokawain B (A), Demethoxycurcumin (B) or 0.1% DMSO for 2 h and then incubated with or without OA (0.2 μM) for 24 h and the cell viability was detected by MTT assay. Results are shown as the mean ± SEM and represent three independent experiments. ###p < 0.001 compared with control group, ***p < 0.001 compared with OA treated group.
FIGURE 11Various constituents suppressed SNP-induced cytotoxicity in SH-SY5Y cells. Cells were pre-treated with different concentrations of Dihydrocapsaicin (A), Rhapontigenin (B), 6-Shogaol (C), 10-Gingerol (D), Nonivamide (E), Carnosol (F), Bavachromene (G) or 0.1% DMSO for 2 h and then incubated with or without SNP (600 μM) for 24 h and the cell viability was detected by MTT assay. Results are shown as the mean ± SEM and represent three independent experiments. ###p < 0.001 compared with control group, *p < 0.05, **p < 0.01, ***p < 0.001 compared with SNP treated group.
FIGURE 12Various constituents suppressed H2O2-induced cytotoxicity in SH-SY5Y cells. Cells were pre-treated with different concentrations of Nonivamide (A), 3,4-Dimethoxycinnamic acid (B) or 0.1% DMSO for 2 h and then incubated with or without H2O2 (400 μM) for 24 h and the cell viability was detected by MTT assay. Results are shown as the mean ± SEM and represent three independent experiments. ###p < 0.001 compared with control group, *p < 0.05, **p < 0.01, ***p < 0.001 compared with H2O2 treated group.
FIGURE 13Various constituents suppressed LPS-induced cytotoxicity in BV2 cells. Cells were pre-treated with different concentrations of Dihydrocapsaicin (A), 6-Shogaol (B), 10-Gingerol (C), Carnosol (D), Cardamonin (E), Bavachromene (F) or 0.1% DMSO for 2 h and then incubated with or without LPS (500 ng/ml) for 24 h and the cell viability was detected by MTT assay (n = 3). NO concentration was detected by Griess reagent kit (n = 3). ###p < 0.001 compared with control group, *p < 0.05, **p < 0.01, ***p < 0.001 compared with LPS treated group.
The targets for molecular docking and their PDB ID, RMSD value and -CDOCKER energy of Nonivamide and the co-crystallized ligands.
| PDB ID | Target | RMSD | -CDOCKER energy of Nonivamide (kcal/mol) | -CDOCKER energy of co-crystallized ligand (kcal/mol) |
|---|---|---|---|---|
| 3D3L | ALOX12 | - | 46.2326 | - |
| 4EY7 | ACHE | 0.8728 | 47.2016 | 22.3205 |
| 6PSJ | ESR1 | 0.789 | 46.8624 | 39.6072 |
| 1S2Q | MAOB | 0.6941 | 54.5295 | 106.263 |
| 5IKR | PTGS2 | 0.4059 | 29.2316 | 36.6139 |
FIGURE 15The receptor-ligand interaction of Nonivamide with the active site of ALOX12 (A, B), ACHE (C, D), ESR1 (E, F), MAOB (G, H), PTGS2 (I, J). The ligand was highlighted in yellow in 3D model diagrams.